CVE:GAPPharmaGap Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PharmaGap Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartHeadlinesSocial Media PharmaGap Inc. (PharmaGap) is a development-stage company. The Company is principally engaged in drug development and out-licensing of drug compounds. The Company is focused on the development of novel drugs for treatment of cancer and other human disease conditions. PharmaGap's lead drug compound, GAP-107B8, is in the pre-clinical testing stage and has shown in vitro and in vivo efficacy in selected cancer types. During the year ended December 31, 2011, the Company commenced specific programs to further elucidate information regarding the pharmacokinetics and toxicity profiles of GAP-107B8. A program to develop liposomal delivery formulations of GAP-107B8 in order to optimize the delivery and safety of the drug compound was completed during 2011. The Company is developing GAP-107B8 for first clinical trials in ovarian cancer, using the intra-peritoneal route of administration.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for PharmaGap. Previous Next 2.2 Community Rank Outperform VotesPharmaGap has received 37 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPharmaGap has received 49 “underperform” votes. (Add your “underperform” vote.)Community SentimentPharmaGap has received 56.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about PharmaGap and other stocks. Vote “Outperform” if you believe GAP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GAP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPharmaGap does not currently pay a dividend.Dividend GrowthPharmaGap does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PharmaGap insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry N/A Sub-IndustryN/A SectorN/A Current SymbolCVE:GAP Previous Symbol CUSIPN/A CIKN/A WebN/A Phone+1-613-2873118Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable TSXV:GAP Rates by TradingView Receive GAP News and Ratings via Email Sign-up to receive the latest news and ratings for GAP and its competitors with MarketBeat's FREE daily newsletter. PharmaGap (CVE:GAP) Frequently Asked Questions Has PharmaGap been receiving favorable news coverage? Headlines about GAP stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. PharmaGap earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutPharmaGap. What is PharmaGap's stock symbol? PharmaGap trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GAP." How do I buy shares of PharmaGap? Shares of GAP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. How can I contact PharmaGap? PharmaGap's mailing address is 1000 Innovation Drive, Suite 400, OTTAWA, ON K2K 2K7, Canada. The company can be reached via phone at +1-613-2873118. This page was last updated on 5/27/2020 by MarketBeat.com Staff
